

# TOM E. HUGHES, PhD

---

## EDUCATION

Doctorate in Pharmacy Administration 1993  
College of Pharmacy, The University of Arizona, Tucson, AZ  
Minor in Management and Policy

Bachelor of Science Pharmacy 1984  
College of Pharmacy, Oregon State University, Corvallis, OR

## PROFESSIONAL EXPERIENCE

### CONSULTING

Principal, Strategic Evidence L.L.C. 2015 – present

### OPTUM

Director  
Product Value Strategy Consulting 2010 – 2014

### LILLY

US Payer Marketing Advisor 2008 – 2010  
Neuroscience / New Product Planning Advisor  
US Managed Markets Group

Senior Portfolio Scientist 2005 – 2008  
US Health Outcomes Research

Senior Outcome Liaison Scientist 2002 – 2005  
US Health Outcomes Research

Director 2000 – 2002  
Global Health Outcomes Research

Health Outcomes Research Scientist 1999 – 2000  
US Health Outcomes Research

Director 1995 – 1999  
Health Outcomes Research, PCS Health Systems

Health Outcomes Research Scientist 1993 – 1995  
Global Health Outcomes Research

## COMMITTEES AND HONORS

PhRMA Health Outcomes Committee 2002 – 2004

Recognition Award: Economic, Social and Administrative Pharmacy, College of Pharmacy, Florida A&M University	2001
ASHP Research and Education Foundation Pharmacy Practice Research Award	1995
Dean's Award – Oregon State University, College of Pharmacy	1983

## **POSTER PRESENTATIONS**

Neumann P, Lin P, Hughes T. FDAMA 114: Understanding its Use in The Era of Comparative Effectiveness. ISPOR, Baltimore, Maryland, May 22 – 25, 2011.

Soumerai S, et al. Discontinuities in atypical antipsychotic therapy following prior authorization with step therapy among Medicaid beneficiaries with schizophrenia. Society of General Medicine annual meeting, Toronto, Canada, April 25, 2007.

Soumerai S, Zhang F, Ross-Degnan D, Ball D, Lecates R, Law MR, Hughes T, Chapman D, Adams AS (2007) Discontinuities in atypical antipsychotic therapy following prior authorization and step therapy among Medicaid beneficiaries with schizophrenia. Academy Health Annual Research Meeting, Orlando, Florida, June 3-5, 2007.

Ohsfeldt R, et al. Cost-effectiveness of a diabetes education program in Medicaid patients. American Diabetes Association of Diabetes Educators annual meeting. San Diego, California, June 2005.

Ohsfeldt R, et al. Economic evaluation of diabetes education program in Medicaid patients. American Association of Diabetes Educators annual meeting. Washington, D.C., August 2005.

Way K, Young C, Opland E, Whitehouse D, Hughes T. Using outcomes research to demonstrate quality improvements for NCQA accreditation: A Case Study. ISPOR. Crystal City, Virginia, May 25, 1999.

Hughes T, Coons S, Kaplan R, Draugalis J. Reweighting the Quality of Well-Being Scale in HIV-infected subjects. A poster presentation at the Inaugural Meeting of the International Health- Related Quality of Life Society. Brussels, Belgium February 3, 1994.

Hughes T, Larson L. Procedural justice in health care decisions: The effect of patient participation. A poster presentation at the 138<sup>th</sup> Annual Meeting of the American Pharmaceutical Association National Meeting. New Orleans, Louisiana, March 10, 1991.

## **PODIUM PRESENTATIONS**

Hughes T, Bayliss M. Patient Reported Outcomes, are they relevant to US payers? Market Access World 2014, Boston, Massachusetts, October 22, 2014.

Neumann P, Hughes T, Radensky P. FDA actions against health economic promotions, 2002–2011. Center for the Evaluation of Value and Risk in Health. Tufts webinar. September 4, 2012.

Neumann P, Hughes T, Radensky P. FDAMA Section 114 in an era of comparative effectiveness research. Center for the Evaluation of Value and Risk in Health. Tufts webinar. September 29, 2011.

Hughes T, Coons S, Kaplan R, Draugalis J. Evaluation of the linearity of the Quality of Well-Being scale using Functional Measurement Theory. A podium presentation at the Inaugural Meeting of the International Health-Related Quality of Life Society, Brussels, Belgium, February 3, 1994.

Hughes T, Coons S, Kaplan R, Draugalis J. Comparison of the construct validity of the Quality of Well-Being scale and The MOS-HIV-34 Health Survey in HIV- Infected Subjects. A poster presentation at the Inaugural Meeting of the International Health-Related Quality of Life Society. Brussels, Belgium February 3, 1994.

Edwards A, Hughes T, Coons S. Health-Related Quality of Life assessment in HIV-infected patients. A podium presentation at the International AIDS Conference, Berlin, Germany, June 1993.

Hughes T, Larson L. Patient-physician Interaction in Drug Selection: The effects of procedural justice. A podium presentation at the 137<sup>th</sup> Annual Meeting of the American Pharmaceutical Association National Meeting, Washington D.C., March 11, 1990.

Hughes T, Larson L. Participation status among staff pharmacists and managers. A podium presentation at the 136<sup>th</sup> Annual Meeting of the American Pharmaceutical Association, Anaheim, California, March 14, 1989.

## **PUBLICATIONS**

Neumann P, Lin P, Hughes T. US FDA Modernization Act, Section 114: Uses, opportunities and implications for comparative effectiveness research. *Pharmacoeconomics* 2011; 29(8) 687-692.

Soumerai S, Zhang F, Ross-Degnan D, Ball D, Lecates R, Law M, Hughes T, Chapman D, Adams A. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. *Health Affairs*. 2008. 27,3:185-195.

Balamurugan A, Ohsfeldt R, Hughes T, Phillips M. Diabetes self-management education program for Medicaid recipients: a continuous quality improvement process. *Diabetes Educator*. November/December 2006; 32: 893 - 900.

Stockl K, Hughes T, Jarar M, Secnik K, Perwein A. Physician perceptions of the use of medications for attention deficit hyperactivity disorder. *JMCP*. 2003;9:416-423.

Way K, Young C, Opland E, Whitehouse D, Hughes T. Drug therapy antidepressant utilization patterns in a national managed care organization. *Drug Benefit Trends* 1999 11(9): 6-11.

Hughes T, Kaplan R, Coons S, Draugalis J, Johnson J, Patterson T. Construct validity of the Quality of Well-Being Scale and the MOS-HIV-34 Health Survey in HIV-infected patients. *Medical Decision Making*, 1997;17:439-446.

Hughes T, Faulkner D, Gibson P. The role of population research in disease prevention and management: Teaching a new dog old tricks. *Disease Management & Health Outcomes* 1997 1(1): 1-7.

Hughes T. Research in Managed Care: Outcomes research in disease prevention and management. *Journal of Managed Care Pharmacy* 1996; 2(3): 212-222.

Copfer A, Ampel N, Hughes T, Gregor K, Dois C, Coons S, Colgan K, Wu A. The use of two measures of Health Related Quality of Life in HIV-infected individuals: a cross-sectional comparison. *Quality of Life Research* 1996; 5: 281-286.

Sclar D, Robison L, Skaer T, Galin R, Legg R, Nemic N, Hughes T, Buesching D, Morgan M. Antidepressant pharmacotherapy: Economic evaluation of fluoxetine, paroxetine, and sertraline in a health maintenance organization. *The Journal of International Medical Research* 1995; 23: 395-412.

Hughes T, Coons S, Kaplan R, Draugalis J. Evaluation of the linearity of the Quality of Well-Being Scale using Functional Measurement Theory. *Quality of Life Research* 1994; 3(1): 47.

Sclar D, Robison L, Skaer T, Legg R, Nemic N, Galin R, Hughes T, Buesching D. Antidepressant Pharmacotherapy: Economic outcomes in a health maintenance organization. *Clinical Therapeutics* 1994; 16(4): 715-730.

Hughes T. Letter to the Editor. *Pharmacoeconomics* 1993; 4(5): 397-398.

Hughes T, Larson LN. Patient involvement in health care: A procedural justice viewpoint. *Medical Care* 1991; 29(3): 297-303.

Hughes T, Larson LN. Participation status among staff pharmacists and managers. *Journal of Pharmaceutical Marketing and Management* 1990; (2): 77-89.

Hughes T, McGhan W. Evaluating the use of participative decision making in hospital pharmacy practice. *American Journal of Hospital Pharmacy* 1989; 46(1): 136-138.